Offering hope to people with MS
For over a decade, EMD Serono, Canada, has offered its ongoing commitment to people with Multiple Sclerosis (MS). Through groundbreaking science and patient-friendly drug delivery systems, we help patients live fuller and more satisfying lives.
In addition, Merck KGaA, Darmstadt, Germany, conducts extensive research in the area of neurodegenerative diseases in order to offer new therapeutic options to patients with high unmet medical needs.
More about Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic disease of the central nervous system, which includes the brain, spinal cord and optic nerves. It is the most common neurological disease in young adults, affecting approximately two million people worldwide, and 50,000 - 70,000 in Canada.
Currently there is no cure for MS but the condition has become increasingly manageable with the help of disease modifying drugs (DMDs).
DMDs help to change the course of the disease by reducing the number of relapses. In addition, some DMD’s are also proven to reduce the severity of relapses, slow the progression of physical disability, and to reduce the number and volume of lesions in the brain.
Multiple Sclerosis at a glance
MS is a complex, multifaceted disease of the central nervous system (CNS) with multiple pathways.
MS interferes with the brain’s ability to control such functions as seeing, walking and talking. It is unpredictable and every person with MS will have his or her unique set of symptoms.
It can be difficult to diagnose, although technologies including magnetic resonance imaging (MRI) and optical coherence tomography (OCT) are improving the ability to diagnose and treat MS earlier.
MS is usually diagnosed between the ages of 20 and 40 and is twice as common among women as it is among men.
Symptoms vary, ranging from mild to more severe, but most commonly include: blurred vision, problems with strength and coordination, and numbness or tingling in the limbs.
The most common form of MS is called relapsing-remitting MS, where symptoms come and go in a pattern of relapse and remittance over time. Other forms of MS are defined by the level of disability progression and the presence or absence of MS attacks.